Get the Stockscreener App
8.47
1.17%
-0.10
Pre-market:
8.46
-0.010
-0.12%
Kura Oncology Inc stock is traded at $8.47, with a volume of 1.15M.
It is down -1.17% in the last 24 hours and down -20.32% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
See More
Previous Close:
$8.57
Open:
$8.46
24h Volume:
1.15M
Relative Volume:
0.64
Market Cap:
$737.04M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-3.9032
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
-1.51%
1M Performance:
-20.32%
6M Performance:
+35.96%
1Y Performance:
+7.08%
1-Day Range:
$8.355
$8.615
1-Week Range:
$8.355
$9.175
52-Week Range:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.47 | 745.74M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Kura oncology CSO Burrows sells $11k in shares By Investing.com - Investing.com India
Kura Oncology’s chief medical officer, Leoni, sells $69k in stock By Investing.com - Investing.com South Africa
Kura Oncology CCO Powl sells $54,266 in stock By Investing.com - Investing.com Australia
Kura Oncology SVP sells $60k in shares By Investing.com - Investing.com India
Kura Oncology COO Ford sells $15,339 in stock - Investing.com
Kura Oncology SVP sells $60k in shares - Investing.com
Kura Oncology’s chief legal officer sells $94,827 in stock - Investing.com
Kura Oncology CCO Powl sells $54,266 in stock - Investing.com
Kura oncology CSO Burrows sells $11k in shares - Investing.com
Understanding Momentum Shifts in (KURA) - Stock Traders Daily
Sector Gamma AS Takes $3.88 Million Position in Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology, Inc. (KURA) Rating Update: 258% Potential Upside Highlights Growth Potential In Biotech Sector - DirectorsTalk Interviews
Kura Oncology (NASDAQ:KURA) Cut to "Strong Sell" at Zacks Research - MarketBeat
Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy (NASDAQ:KURA) - Seeking Alpha
Kura Oncology (NASDAQ:KURA) Nasdaq 100 Index Clinical Research Focus - Kalkine Media
Jim Cramer calls Kura speculative but says "It's one of the stronger ones I've seen in a very long time" - MSN
Does Kura Oncology (NASDAQ:KURA) Have A Healthy Balance Sheet? - 富途资讯
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Up 37.5% in December - MarketBeat
Kura Oncology's finance SVP sells shares worth $38,958 - MSN
Kura Oncology price target lowered to $20 from $25 at Leerink - Yahoo Finance
FY2025 EPS Forecast for Kura Oncology Reduced by Analyst - MarketBeat
Kura Oncology (KURA) Receives a Buy from Leerink Partners - The Globe and Mail
Inflation Data: Will Kura Oncology Inc stock keep outperforming rivalsJuly 2025 PreEarnings & Risk Controlled Swing Alerts - Bộ Nội Vụ
KURA: HC Wainwright & Co. Reiterates 'Buy' Rating and $40 PT | K - GuruFocus
Kura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC Wainwright - MarketBeat
Stock Recap: Whats the profit margin of Kura Oncology IncIPO Watch & AI Based Trade Execution Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Kura Oncology (KURA) - The Globe and Mail
Kura Oncology 8-K Filing Analysis - TradingView
Kura Oncology Posts $2.1M Initial KOMZIFTI Sales, Secures $195M Milestone - Nasdaq
Kura Oncology Announces Launch of KOMZIFTI™ (ziftomenib) and Preliminary $2.1 Million Revenue Following FDA Approval for R/R NPM1-mutated AML - Quiver Quantitative
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - The Manila Times
Kura Oncology wins FDA approval for leukemia drug - MSN
Is Kura Oncology Inc. stock affected by interest rate hikesTrade Performance Summary & Fast Gain Stock Tips - Улправда
How Komzifti Is Rewriting The Kura Oncology (KURA) Story For Analysts And Investors - Yahoo Finance
Can Kura Oncology Inc. stock sustain institutional interestJuly 2025 Selloffs & Daily Entry Point Trade Alerts - Улправда
Rate Cut: Will Kura Oncology Inc. stock see insider buyingEarnings Summary Report & Consistent Return Strategy Ideas - Улправда
Aug Intraday: Is Kura Oncology Inc. stock affected by interest rate hikesWeekly Stock Analysis & Verified Swing Trading Watchlist - Улправда
FY2025 EPS Forecast for Kura Oncology Decreased by Analyst - MarketBeat
Research Analysts Set Expectations for Kura Oncology FY2030 Earnings - MarketBeat
Kura Oncology (NASDAQ:KURA) Stock Price Down 6.1%Here's Why - MarketBeat
Kura Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Kura Oncology (KURA) Grants Stock Options to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Discipline and Rules-Based Execution in KURA Response - Stock Traders Daily
What analysts say about Kura Oncology Inc stockGeopolitical Risk Analysis & Affordable Trading Portfolio - earlytimes.in
Is Kura Oncology Inc a good long term investmentPrice-to-Book Ratio Updates & Maximize Gains Professionally - earlytimes.in
Kura Oncology Stock: Biotech Battleground With High Hopes And Higher Volatility - AD HOC NEWS
Kura Oncology shows market leadership with jump to 93 RS rating - MSN
Kura Oncology rises following Jim Cramer comments - MSN
(KURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):